Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients

Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate the utility of plasma cell-free DNA (cfDNA) as a prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaorong, Li, Chenchen, Zhang, Zhao, Li, Daniel Y., Du, Jinwei, Ding, Ping, Meng, Haiyan, Xu, Hui, Li, Ronglei, Ho, Effie, Zhang, Aiguo, Okunieff, Paul, Lu, Jianwei, Sha, Michael Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027214/
https://www.ncbi.nlm.nih.gov/pubmed/33828112
http://dx.doi.org/10.1038/s41598-021-85797-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027214/
https://www.ncbi.nlm.nih.gov/pubmed/33828112
http://dx.doi.org/10.1038/s41598-021-85797-z

Ejemplares similares